Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
25 Novembre 2024 - 2:05PM
Business Wire
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the
Company), a clinical stage biopharmaceutical company focused on
discovering and developing novel, oral small molecule therapies
that target biological pathways associated with specific clinical
impairments in the treatment of neuroscience, inflammation and
immunology (NI&I) indications, today announced that management
is scheduled to participate in a fireside chat at the 7th Annual
Evercore HealthCONx Conference in Miami on Wednesday, December 4,
2024 at 11:15 a.m. ET.
An audio webcast of the fireside chat can be accessed on the
Investors section of Contineum’s website. A webcast replay will
also be available.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage
biopharmaceutical company focused on discovering and developing
novel, oral small molecule therapies for NI&I indications with
high unmet need. Contineum is focused on targeting biological
pathways associated with specific clinical impairments, that
Contineum believes, once modulated, may demonstrably impact the
course of disease. Contineum has a pipeline of internally-developed
programs to address multiple NI&I disorders. Contineum has two
drug candidates in clinical trials, PIPE-791, an LPA1 receptor
antagonist in clinical development for idiopathic pulmonary
fibrosis, progressive multiple sclerosis and chronic pain, and
PIPE-307, a selective inhibitor of the M1 receptor in clinical
development for relapsing-remitting multiple sclerosis. PIPE-307 is
being developed pursuant to a global license and development
agreement between Contineum and Janssen Pharmaceutica NV, a Johnson
& Johnson company, who has also announced plans to initiate a
Phase 2 trial of PIPE-307 in depression in 2024. For more
information, please visit www.contineum-tx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241125236974/en/
Steve Kunszabo Contineum Therapeutics Senior Director, Investor
Relations & Corporate Communications 858-649-1158
skunszabo@contineum-tx.com
Grafico Azioni Contineum Therapeutics (NASDAQ:CTNM)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Contineum Therapeutics (NASDAQ:CTNM)
Storico
Da Dic 2023 a Dic 2024
